On April 22, 2026, Hers — the women's health arm of Hims & Hers Health — launched a dedicated menopause and perimenopause specialty, offering estrogen patch kits starting at $134 per month. The launch makes Hers one of the largest direct-to-consumer telehealth platforms now prescribing hormone replacement therapy (HRT) for menopausal symptoms, and it lands during an active US estrogen patch shortage that industry sources have told Reuters could persist for up to three years. Hims & Hers stock closed up about 7% on the announcement; Bank of America raised its price target to $30 from $25.

Why It Matters

Menopause care has been femtech's largest under-served segment for a decade — 1.3M US women enter menopause each year, 80%+ report sexual health symptoms, and until recently most HRT was prescribed by primary care physicians with minimal specialization. Hers' $134/month pricing is deliberately aggressive vs. specialty clinics like Evernow and Midi Health (typically $75–$150 subscription plus separate medication costs) and positions Hers as the mass-market consumer platform for an $18B+ annual HRT market. For existing menopause-specific startups (Joylux, Womaness, Gennev, Evernow, Midi, Elektra), Hers' scale and trusted consumer brand is now the biggest competitive threat. Expect Hers to also vertically integrate — partnering with generic patch manufacturers to lock in supply and further differentiate on reliability while everyone else faces stockouts. This is a meaningful femtech story: the telehealth consolidation that transformed male sexual health (ED, TRT, hair loss) is now arriving for menopause, and Hers is the first mover at scale.

The Hers menopause offering includes a physician consultation, transdermal estrogen patches, and progesterone "where clinically appropriate." Patients can adjust treatment plans over time in consultation with clinicians, and the Hers app includes educational modules on sleep, nutrition, and wellness tailored to perimenopause and menopause transitions. The company emphasized it has "secured sufficient inventory" to serve eligible patients without disruption — an unusual supply-chain claim in a category where independent pharmacies and CVS/Walgreens have reported intermittent out-of-stock notices since mid-2025.

The backstory on the estrogen shortage is directly relevant. In March 2026, the FDA removed 23-year-old black-box warnings from menopausal HRT products after reviewing updated evidence that the original Women's Health Initiative (WHI) findings overstated cardiovascular and breast cancer risks for most women. The warning removal triggered a surge in prescription demand that has outpaced the generic manufacturer base; Amneal, one of the largest generic patch makers, publicly confirmed a significant demand increase in an earlier story Afterglow covered. Hers' entry on April 22 essentially creates a managed pathway for patients stuck between the new FDA guidance (take HRT) and a supply constraint (patches out of stock at local pharmacy).

The Hers menopause launch is also part of a multi-quarter trajectory: the company disclosed in October 2025 that "Hers" (women's health) is targeted to reach $1B in 2026 revenue, with menopause and perimenopause specifically flagged as the next major vertical. Hims & Hers' acquisition of Eucalyptus (closed March 2026, up to $1.15B) also brought UK women's health brands into the portfolio, and the telehealth infrastructure for hormone therapy was already built for the TRT / testosterone business on the Hims side.

Sources

Update — 2026-04-24

Initial entry — story first created.